|
|
|
|
|
|
|
|
"Recent and continuing developments in high-throughput and multiplexed assay platforms as well as in disciplines such as bioinformatics and biostatistics will surely shape the future of clinical trials. Application of novel techniques in a comprehensive approach, revealing the interrelations among targets and the mechanisms of action underlying cancer (systems biology), may lead to comprehensive diagnostic tools (systems pathology) and specific combinations of drugs (cocktails of monoclonal antibodies, RNA therapeutics, or others) in what has been called the actualization of personalized medicine. We know that momentum in the era of targeted therapy will continue to accelerate, bringing new hope to our patients
with cancer and their families"
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.